Walley T, Folino-Gallo P, Schwabe U, Van Ganse E, Stephens P
Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembrooke Place, Liverpool, L69 3GF, UK.
Eur J Clin Pharmacol. 2004 Sep;60(7):503-11. doi: 10.1007/s00228-004-0801-9.
To compare data on statin utilisation and costs across Europe from routine administrative databases with those from a commercial source.
Observational study in European Union member states and Norway. Comparison of data collected from national administrative databases used to reimburse pharmacists and data from a standard commercial source (Intercontinental Marketing Services Health): detailed data by drug for the year 2000.
There were differences among the data from administrative databases and those from the commercial source; these differences were of a consistent pattern in each country. In general, the commercial data recorded greater utilisation (reflecting both public and private use, range from 0 to +55%, median +15%), lower cost per defined daily doses (as commercial data sources used ex-factory price rather than expenditure to the state used in administrative databases, range from -70% to -6%, median -39%) and similar utilisation per 1000 head of population per day (range from -15 to +47%, median -1%).
Administrative databases can give useful utilisation data, which are broadly comparable with those from commercial sources. Cost data differ more, and the figures for each may be useful in different settings. Standards for data collection from the administrative databases are required.
比较来自常规管理数据库的欧洲他汀类药物使用情况和成本数据与来自商业来源的数据。
在欧盟成员国和挪威开展观察性研究。比较从用于偿付药剂师的国家管理数据库收集的数据和来自标准商业来源（洲际营销服务健康）的数据：2000年按药物分类的详细数据。
管理数据库的数据与商业来源的数据存在差异；这些差异在每个国家都呈现出一致的模式。总体而言，商业数据记录的使用量更高（反映公共和私人使用情况，范围从0至+55%，中位数为+15%），每限定日剂量的成本更低（因为商业数据来源使用出厂价而非管理数据库中使用的国家支出，范围从-70%至-6%，中位数为-39%），且每天每千人口的使用量相似（范围从-15至+47%，中位数为-1%）。
管理数据库可提供有用的使用数据，这些数据与商业来源的数据大致可比。成本数据差异更大，且每种数据在不同情况下可能都有用。需要制定管理数据库数据收集的标准。
